These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1378038)

  • 21. Relative roles of hCD46 and hCD55 in the regulation of hyperacute rejection.
    Verbakel CA; Bonthuis F; Eerhart SE; van Dixhoorn M; Grosveld F; Marquet RL; IJzermans JN
    Transplant Proc; 2000 Aug; 32(5):903-4. PubMed ID: 10936266
    [No Abstract]   [Full Text] [Related]  

  • 22. Human CD46 rather than CD55 is a key element in protection against complement activation in vitro.
    van Dixhoorn MG; Dekker S; Janssen RW; Verbakel CA; Grosveld F
    Transplant Proc; 2000 Aug; 32(5):916-8. PubMed ID: 10936272
    [No Abstract]   [Full Text] [Related]  

  • 23. Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis.
    Loveland BE; Johnstone RW; Russell SM; Thorley BR; McKenzie IF
    Transpl Immunol; 1993; 1(2):101-8. PubMed ID: 8081768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement regulatory molecules: application to therapy and transplantation.
    Morgan BP
    Immunol Today; 1995 Jun; 16(6):257-9. PubMed ID: 7544975
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative efficacy of immunosuppressive drugs in xenografting.
    Thomas FT; DeMasi RJ; Araneda D; Marchman W; Alqaisi M; Larkin EW; Condie RM; Carobbi A; Thomas JM
    Transplant Proc; 1990 Jun; 22(3):1083-5. PubMed ID: 1693452
    [No Abstract]   [Full Text] [Related]  

  • 26. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
    Kroshus TJ; Salerno CT; Yeh CG; Higgins PJ; Bolman RM; Dalmasso AP
    Transplantation; 2000 Jun; 69(11):2282-9. PubMed ID: 10868627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases.
    Miwa T; Song WC
    Int Immunopharmacol; 2001 Mar; 1(3):445-59. PubMed ID: 11367529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ancient proteins and futuristic surgery: the role of complement in discordant xenograft rejection.
    Winkler M
    Transplant Proc; 2001; 33(7-8):3862-4. PubMed ID: 11750645
    [No Abstract]   [Full Text] [Related]  

  • 29. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
    Capey S; van den Berg CW
    Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejection.
    Yannoutsos N; Ijzermans JN; Harkes C; Bonthuis F; Zhou CY; White D; Marquet RL; Grosveld F
    Genes Cells; 1996 Apr; 1(4):409-19. PubMed ID: 9135084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement.
    Wang MW; Wright LJ; Sims MJ; White DJ
    Scand J Immunol; 1991 Dec; 34(6):771-8. PubMed ID: 1721235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunology of xenotransplantation.
    White DJ; Van der Borgarde J; Lim SM
    Ann Acad Med Singap; 1991 Nov; 20(6):770-6. PubMed ID: 1803967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C5b-8 step lysis of swine endothelial cells by human complement and functional feature of transfected CD59.
    Miyagawa S; Mikata S; Shirakura R; Matsuda H; Nagasawa S; Terados A; Hatanaka M; Matsumoto M; Seya T
    Scand J Immunol; 1996 Apr; 43(4):361-6. PubMed ID: 8668913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.
    Parker CJ
    Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):36-42. PubMed ID: 1718642
    [No Abstract]   [Full Text] [Related]  

  • 36. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
    Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
    Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Xenograft].
    Kemp E; Hellerström C
    Nord Med; 1994; 109(12):335-7. PubMed ID: 7997370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model.
    Lin Y; Sobis H; Vandeputte M; Waer M
    Transplant Proc; 1995 Feb; 27(1):305-6. PubMed ID: 7879012
    [No Abstract]   [Full Text] [Related]  

  • 39. Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates.
    Adams DH; Kadner A; Chen RH; Farivar RS
    Xenotransplantation; 2001 Feb; 8(1):36-40. PubMed ID: 11208189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of complement-mediated liver damage and protection in control and transgenic mice for human complement blockers MCP and DAF.
    Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Marinucci G; Melli CM; Bruzzone P; Alfani D; Cortesini R; Rossini M
    Transplant Proc; 1996 Feb; 28(1):127-9. PubMed ID: 8644143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.